Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

November 4, 2019

Veru Completes Enrollment for Zuclomiphene Citrate Trial for ADT-Induced Hot Flashes in PC

News

Veru Healthcare has completed patient enrollment for its Phase 2 clinical trial evaluating the use of zuclomiphene citrate (VERU-944) for the treatment of hot flashes in men receiving hormone ... Read more

October 23, 2019

FDA Grants Breakthrough Device Designation to IsoPSA Blood Test for Early Prostate Cancer Diagnosis

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Cleveland Diagnostics’ IsoPSA, a minimally invasive blood test for early detection of prostate cancer. The IsoPSA ... Read more

October 16, 2019October 25, 2019

Long-term Hormone Therapy Does More Harm than Good in Prostate Cancer Patients with Low PSA Levels After Surgery, Analysis Shows

News

Men who see their prostate cancer returning after surgery see no benefits from adding long-term hormone therapy to salvage radiation therapy if their PSA levels are low; instead, they ... Read more

September 23, 2019

Prolaris Helps to ID Prostate Cancer Patients Suited for Active Surveillance, Study Says

News

Prolaris, a genetic test developed by Myriad Genetics to help predict the aggressiveness of prostate cancer, can accurately identify prostate cancer patients with low-risk disease who may safely opt ... Read more

August 29, 2019

FDA Clears Way for Trial of Immunotherapy in Advanced Prostate Cancer, Scripps Research Says

News

The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment ... Read more

August 21, 2019

Myriad to Seek FDA Approval of Diagnostic Test to Determine Lynparza Eligibility for mCRPC Patients

News

Myriad Genetics is filing an application with the U.S. Food and Drug Administration requesting the approval of its BRACAnalysis CDx — which identifies inherited BRCA mutations — as a ... Read more

August 19, 2019

Phase 1 Trial Enrolling Advanced, Castration-resistent Patients to Test Triple Immunotherapy Combo

News

A Phase 1 trial is enrolling people with metastatic castration-resistant prostate cancer (mCRPC) to test Inovio Pharmaceutical‘s immunotherapy INO-5151 in combination with two other immunotherapies — Celldex’s CDX-301 and Bristol-Myers Squibb’s Opdivo ... Read more

August 8, 2019September 10, 2019

First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer

News

A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r is a tablet formulation of ... Read more

July 31, 2019July 31, 2019

Invitae Offers Free Genetic Testing, Counseling for Hereditary Prostate Cancer

News

Invitae has launched a free genetic testing program to help connect prostate cancer patients to earlier diagnosis and treatments. The program also offers eligible patients free genetic counseling to ... Read more

July 3, 2019

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says

News

Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo ... Read more

Pin It on Pinterest